EPFL BioE Talks SERIES "Targeting TCR and Co-receptor Signaling in T Cell-Mediated Immunity"
Event details
| Date | 20.11.2023 |
| Hour | 16:00 › 17:00 |
| Speaker | Ricardo A. Fernandes, Ph.D., Group Leader, CAMS Oxford Institute, Nuffield Department of Medicine, University of Oxford (UK) |
| Location | Online |
| Category | Conferences - Seminars |
| Event Language | English |
WEEKLY EPFL BIOE TALKS SERIES
Abstract:
The potency of the T cell response against pathogens or cancer cells is determined by the signalling output from two distinct classes of immune receptors: the T cell receptor and co-receptors, which include activating and inhibitory checkpoint receptors such as CD28 or PD-1 and CTLA-4, respectively. Here, we will provide an update on our latest work in targeting T cell receptors and inhibitory receptors to modulate T cell responses.
Bio:
Dr. Ricardo Fernandes is a Group Leader at the CAMS Oxford Institute/NDM and Nuffield Department of Medicine at the University of Oxford. He obtained his PhD at Oxford, working with Simon Davis on the mechanism of TCR triggering. Later moved to Stanford, where he developed novel bispecific proteins that take advantage of endogenous membrane phosphatases to shut down signalling by surface receptors. The Fernandes' Lab applies protein engineering to decipher functional and structural correlates of immune receptor signalling and identify new therapeutic approaches to modulate T cell function in autoimmune and cancer settings.
Zoom link (with one-time registration for the whole series) for attending remotely: https://go.epfl.ch/EPFLBioETalks
Instructions for 1st-year Ph.D. students who are under EDBB’s mandatory seminar attendance rule:
IF you are not attending in-person in the room, please make sure to
Abstract:
The potency of the T cell response against pathogens or cancer cells is determined by the signalling output from two distinct classes of immune receptors: the T cell receptor and co-receptors, which include activating and inhibitory checkpoint receptors such as CD28 or PD-1 and CTLA-4, respectively. Here, we will provide an update on our latest work in targeting T cell receptors and inhibitory receptors to modulate T cell responses.
Bio:
Dr. Ricardo Fernandes is a Group Leader at the CAMS Oxford Institute/NDM and Nuffield Department of Medicine at the University of Oxford. He obtained his PhD at Oxford, working with Simon Davis on the mechanism of TCR triggering. Later moved to Stanford, where he developed novel bispecific proteins that take advantage of endogenous membrane phosphatases to shut down signalling by surface receptors. The Fernandes' Lab applies protein engineering to decipher functional and structural correlates of immune receptor signalling and identify new therapeutic approaches to modulate T cell function in autoimmune and cancer settings.
Zoom link (with one-time registration for the whole series) for attending remotely: https://go.epfl.ch/EPFLBioETalks
Instructions for 1st-year Ph.D. students who are under EDBB’s mandatory seminar attendance rule:
IF you are not attending in-person in the room, please make sure to
- send D. Reinhard a note before noon on seminar day, informing that you plan to attend the talk online, and
- be signed in on Zoom with a recognizable user name (not a pseudonym making it difficult or impossible to be identified).
Practical information
- Informed public
- Registration required
Organizer
- Prof. Bruno Correia, EPFL
Contact
- Institute of Bioengineering (IBI), Dietrich REINHARD